Research output

Residual effects of esmirtazapine on actual driving performance: Overall findings and an exploratory analysis into the role of CYP2D6 phenotype

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

Abstract

Introduction: Esmirtazapine is evaluated as a novel drug for treatment of insomnia. Purpose: The present study was designed to assess residual effects of single and repeated doses of esmirtazapine 1.5 and 4.5 mg on actual driving in 32 healthy volunteers in a double-blind, placebo-controlled study. Treatment with single doses of zopiclone 7.5 mg was included as active control. Methods: Treatments were administered in the evening. Driving performance was assessed in the morning, 11 h after drug intake, in a standardized on-the-road highway driving test. The primary study parameter was standard deviation of lateral position (SDLP), a measure of "weaving". All subjects were subjected to CYP2D6 phenotyping in order to distinguish poor metabolizers from extensive metabolizers of esmirtazapine. Results: Overall, esmirtazapine 1.5 mg did not produce any clinically relevant change in SDLP after single and repeated dosing. Driving impairment, i.e., a rise in SDLP, did occur after a single-dose administration of esmirtazapine 4.5 mg but was resolved after repeated doses. Acute driving impairment was more pronounced after both doses of esmirtazapine in a select group of poor metabolizers (N = 7). A single-dose zopiclone 7.5 mg also increased SDLP as expected. Conclusion: It is concluded that single and repeated doses of 1.5 mg esmirtazapine are generally not associated with residual impairment. Single-dose administration of 4.5 mg esmirtazapine was associated with residual impairment that generally resolved after repeated administration. Exploratory analysis in a small group of poor CYP 2D6 metabolizers suggested that these subjects are more sensitive to the impairing effects of esmirtazapine on car driving. (PsycINFO Database Record (c) 2011 APA, all rights reserved) (journal abstract)
View graph of relations

Details

Original languageEnglish
Pages (from-to)321-332
JournalPsychopharmacology
Volume215
Issue number2
DOIs
Publication statusPublished - 1 Jan 2011